The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
National HealthCare Corporation NHC
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals.
read at $215.54
National HealthCare Corporation holds its Markup at $215.54.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 13 days |
| Price | $215.54 |
| Valuation | 27.35 trailing · 501.26 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.64 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
| Revenue growth | 2.20% |
| Profit margin | 8.10% |
| Debt to equity | 3.59 |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 5.7% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 10.7% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 15.2% of assets, under the 49% limit. Pass
- Revenue purity Only 0.6% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Nursing Home Operator Priced Far Beyond Reality
Picture an elderly resident moving into a modest care home while the bill for the whole chain gets paid at double the fair value. National HealthCare runs inpatient facilities and home hospice services across the United States, yet the market prices it like a high-growth superstar despite 2 percent revenue growth and an 8 percent profit margin.
The numbers give no support for that optimism. A forward multiple of 530 times earnings sits miles above any reasonable return on equity of 12 percent, and our fair value sits at half the current price. The ethical screen clears, but valuation alone removes any investment case.
Low single-digit growth in a mature sector rarely justifies such extremes, and any slip in occupancy or reimbursement rates would expose the gap quickly. Analysis, not advice.
| Forward P/E | 501.3x expensive even after accounting for its growth |
| Trailing P/E | 27.4x a premium valuation |
| Revenue growth | 2.2% slow but positive growth |
| Profit margin | 8.1% thin but positive margins |
| Return on equity | 12.0% a solid return on shareholder capital |
| Debt to equity | 3.59 heavy leverage — higher risk if revenue softens |
| Current ratio | 1.86 healthy short-term liquidity |
| Beta | 0.64 steadier than the market |
| Market cap | $3.4B |
| Employees | 15,278 |
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in NHC's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
NHC trades on NYSE American. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $189.75 | +1.8% | · | $1,018 | +1.8% |
| 2 months | $170.85 | +13.1% | · | $1,131 | +13.1% |
| 3 months | $155.27 | +24.4% | $0.64 | $1,248 | +24.8% |
| 6 months | $136.57 | +41.5% | $1.28 | $1,424 | +42.4% |
| 1 year | $102.33 | +88.8% | $2.56 | $1,913 | +91.3% |
| 2 years | $97.98 | +97.2% | $5.00 | $2,023 | +102.3% |
| 3 years | $57.32 | +237.0% | $7.36 | $3,499 | +249.9% |
| 5 years | $63.69 | +203.3% | $11.78 | $3,218 | +221.8% |
Historical returns from market close data. Past performance does not guarantee future results.